NCT07718347 Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser
| NCT ID | NCT07718347 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Lynch Regenerative Medicine |
| Condition | Immediate Post-Treatment Care |
| Study Type | INTERVENTIONAL |
| Enrollment | 21 participants |
| Start Date | 2026-04-16 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 21 participants in total. It began in 2026-04-16 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
ariessence is intended to be used as a viscous, leave-on solution designed for topical application to the face. It is intended to be used following non-medical cosmetic procedures, performed by licensed healthcare professionals to enhance comfort and maintain skin hydration. This study is designed to be a multi-center, post-market cosmetic evaluation of ariessence applied to the full face after an ablative laser procedure to evaluate improvements in procedure tolerability and improvements in the appearance of the skin, compared to an emollient control.
Eligibility Criteria
Inclusion Criteria -:Adults 40-65 70 years * Glogau III-IV * Fitzpatrick II-IV. * Suitable for ablative laser * non-smoker ≥ 3 years * Willing to comply with post-procedure regimen * patient reported outcome documentation, and photo documentation. Exclusion Criteria: * Fitzpatrick I or \> IV, * recent facial procedures (\< 6 months) * active skin disease * pregnancy/lactation * implanted devices * history of keloids.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07718347 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 70 Years, studying Immediate Post-Treatment Care. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07718347 currently recruiting?
Yes, NCT07718347 is actively recruiting participants. Contact the research team at clinicaltrials@purity-health.com for enrollment information.
Where is the NCT07718347 trial being conducted?
This trial is being conducted at Sacramento, United States, Nashville, United States.
Who is sponsoring the NCT07718347 clinical trial?
NCT07718347 is sponsored by Lynch Regenerative Medicine. The trial plans to enroll 21 participants.